- The FDA has rescheduled a joint meeting of the Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee (ORUDAC) for May 9 & 10, 2023 to review Perrigo Company plc‘s (NYSE:PRGO) Opill daily oral contraceptive for over-the-counter (OTC) use.
- Perrigo announced in July 2022 that its HRA Pharma affiliate filed an application with the FDA for the Rx-to-OTC switch of Opill, a progestin-only daily birth control pill (also called a mini pill or non-estrogen pill).
- If approved, Opill would be the first ever daily birth control pill available OTC, without a prescription, in the U.S.
- Over-the-counter birth control has support from major medical organizations.
- Perrigo had previously expected approval in the first half of 2023, but the original FDA action date was never disclosed.
- Price Action: PRGO shares are up 1.29% at $34.63 on the last check Tuesday.
American Rebel Expands Into The Beverage Industry With The Launch Of American Rebel Beer
– Undertakes Transformational Opportunity in Partnership with Industry Leading Beverage Solutions Company and Largest Co-Packer in the U.S. –Nashville, TN, Oct. 05, 2023 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc.
